Silverarc Capital Management LLC Acquires Shares of 124,388 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Silverarc Capital Management LLC bought a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the 4th quarter, Holdings Channel.com reports. The firm bought 124,388 shares of the biopharmaceutical company’s stock, valued at approximately $5,233,000.

A number of other large investors have also recently made changes to their positions in the company. Hsbc Holdings PLC grew its position in shares of Ultragenyx Pharmaceutical by 195.1% during the fourth quarter. Hsbc Holdings PLC now owns 47,516 shares of the biopharmaceutical company’s stock worth $1,975,000 after acquiring an additional 31,416 shares during the last quarter. Stifel Financial Corp increased its stake in Ultragenyx Pharmaceutical by 13.5% in the fourth quarter. Stifel Financial Corp now owns 23,796 shares of the biopharmaceutical company’s stock valued at $1,001,000 after purchasing an additional 2,835 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Ultragenyx Pharmaceutical by 1,872.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 16,827 shares of the biopharmaceutical company’s stock valued at $708,000 after buying an additional 15,974 shares during the last quarter. First Trust Advisors LP grew its holdings in shares of Ultragenyx Pharmaceutical by 3,097.1% during the fourth quarter. First Trust Advisors LP now owns 544,202 shares of the biopharmaceutical company’s stock worth $22,894,000 after buying an additional 527,180 shares during the last quarter. Finally, Marshall Wace LLP increased its position in Ultragenyx Pharmaceutical by 27.9% in the 4th quarter. Marshall Wace LLP now owns 1,051,573 shares of the biopharmaceutical company’s stock valued at $44,240,000 after acquiring an additional 229,561 shares during the period. 97.67% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Trading Down 0.8 %

RARE stock opened at $35.40 on Tuesday. The stock has a 50-day moving average price of $38.25 and a two-hundred day moving average price of $43.99. The company has a market cap of $3.32 billion, a PE ratio of -5.58 and a beta of 0.61. Ultragenyx Pharmaceutical Inc. has a 12-month low of $29.59 and a 12-month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $164.88 million during the quarter, compared to analysts’ expectations of $163.23 million. Equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 1,785 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the sale, the chief financial officer now owns 106,169 shares in the company, valued at $4,289,227.60. This represents a 1.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the sale, the executive vice president now owns 54,991 shares of the company’s stock, valued at $2,358,014.08. This trade represents a 5.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 124,643 shares of company stock valued at $5,256,268. Corporate insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on RARE. HC Wainwright reissued a “buy” rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Piper Sandler dropped their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a research report on Monday, March 17th. JPMorgan Chase & Co. increased their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an “overweight” rating in a report on Thursday, March 27th. Canaccord Genuity Group increased their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. Finally, Wedbush reissued a “neutral” rating and set a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $92.79.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.